Zukoski Outpatient

Located in Maitland, FL, Zukoski Outpatient operates within the FL regulatory framework as a licensed addiction-treatment provider. The facility's programming is outpatient (Outpatient, Dual Dx), not residential. Structural evaluation of this facility's clinical posture requires review of state licensing records, accreditation status, and payer-network contracts.

Care levels at Zukoski Outpatient

Zukoski Outpatient is an outpatient-focused program (Outpatient, Dual Dx) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. ASAM Criteria 4e level-of-care matching requires clinical assessment across six dimensions (withdrawal potential, biomedical conditions, emotional/behavioral/cognitive conditions, readiness, relapse risk, recovery environment). The alignment of Zukoski Outpatient's offerings to any specific patient's clinical profile should be determined by an independent ASAM-aligned assessment prior to admission.

Insurance and payment

Zukoski Outpatient operates primarily on commercial insurance. The implication for patients: higher typical cost-share, potentially more intensive programming, and the full burden of MHPAEA parity-rule dynamics — including appeal rights when the plan denies. The operational prerequisite for admission is written documentation of: (a) network contract status; (b) prior authorization; (c) cost-sharing structure; (d) medical-necessity criteria applied. Absence of any of these four increases the probability of post-admission financial disagreement.

Specialty programming

The facility's documented specialty programming includes: Clients with co-occurring mental and substance use disorders. Specialty-program verification requires review of: (a) dedicated specialty-track programming hours per week; (b) specialty-credentialed clinical staffing (e.g., LCSW with trauma specialization, perinatal-nurse certification, adolescent-development training); (c) specialty-specific clinical assessment protocols; (d) specialty-specific outcome measurement. Marketing designation alone is insufficient for clinical confidence.

Before you call

Pre-admission due-diligence for Zukoski Outpatient: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via FL behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether Zukoski Outpatient offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.